Find Clinical Trials

Answer each question to find trials that best match your clinical situation. You can leave questions blank if you do not know the answer.

This search will output a list of trials for which you may be eligible based on the criteria you enter.

I want to enter information about my cancer and treatments
I want to filter the trials based on location, phase of development, tumor genomic alteration, or drug name, category or target
No preference
FRalpha
No preference

Matching Trials

For more detailed information please click on the clinical trial number and you will be taken to the clinicaltrials.gov website.
For a key to the icons and text used in the Results column, please click here.
To learn more about our trial annotation process, results assignments, and the criteria used to highlight drugs with promising results, please click here.

  Clinical Trial Phase Eligible Participant Official Title Location Drugs in Trial Results
NCT05870748II/IIIPlatinum resistant FOLR+ high grade serous ovarian cancer with prior bevacizumab (Phase III)REFRaME-O1: A Phase 2/3 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) Versus Investigator's Choice (IC) Chemotherapy in Women With Relapsed Platinum-resistant Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor Alpha (FOLR1)AZ, CA, DC, FL, MD, MA, MN, NE, NM, NY, OH, OK, OR, PA, TX, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
GemcitabineGemzarRibonucleotide reductase and DNA synthesis inhibitorApproved in Ovarian Cancer
Liposomal doxorubicinPegylated Liposomal Doxorubicin Hydrochloride, liposomal doxorubicin, LipoDox, Evacet, Dox-SL, DoxilTopoisomerase II inhibitorApproved in Ovarian Cancer
Luveltamab tazevibulinSTRO-002, anti-folate receptor-alpha antibody drug conjugate STRO-002ADC: anti-FRalpha + microtubule destabilizer (SC209)Clinical Trials
PaclitaxelAnzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, TXLMicrotubule stabilizer/mitotic inhibitorApproved in Ovarian Cancer
TopotecanHycamptamine, Hycamtin, TOPOTopoisomerase I inhibitorApproved in Ovarian Cancer
NCT05613088IIPlatinum resistant ovarian cancer (at most one prior therapy for platinum resistant disease)A Phase 2 Open-label Randomized Study of Farletuzumab Ecteribulin (MORAb-202), a Folate Receptor Alpha-targeting Antibody-drug Conjugate, Versus Investigator's Choice Chemotherapy in Women With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube CancerCA, CO, FL, MI, NY, NC, OH, WAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Farletuzumab ecteribulinMORAb-202ADC: anti-FRalpha + microtubule destabilizer (eribulin)Clinical Trials
NCT05579366I/IIRecurrent ovarian cancer (Phase II)Phase 1/2 Study of PRO1184 in Patients With Locally Advanced and/or Metastatic Solid TumorsCA, KS, MA, MI, OK, TN, TX, UT, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Bevacizumabimmunoglobulin G1 (human-mouse monoclonal rhuMab-VEGF gamma-chain, anti-VEGF monoclonal antibody, AvastinVEGF antagonistApproved in Ovarian Cancer
CarboplatinParaplatin, NovoplatinumDNA damaging agentApproved in Ovarian Cancer
Rinatabart sesutecanPRO1184ADC: anti-FRalpha + topoisomerase I inhibitor (exatecan)Clinical Trials
NCT04300556I/IIPlatinum resistant ovarian cancerA Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Subjects With Selected Tumor TypesCA, FL, GA, IL, MD, NJ, NY, OH, VAView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
Farletuzumab ecteribulinMORAb-202ADC: anti-FRalpha + microtubule destabilizer (eribulin)Clinical Trials
NCT05797168I/IIAdvanced solid tumorsFONTANA: A Modular Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of AZD5335 Monotherapy and in Combination With Anti-cancer Agents in Participants With Solid Tumors.CA, CO, KY, MA, OH, OR, RI, TXView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
AZD5335anti-FRa antibody-drug conjugate AZD5335ADC: anti-FRalpha + topoisomerase I inhibitor (AZ14170132)Clinical Trials
SaruparibAZD5305PARP1 inhibitorClinical Trials
NCT06400472IAdvanced solid tumors (inc ovarian expansion)A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4170156, an Antibody-Drug Conjugate Targeting Folate Receptor α-Expressing Tumor Cells, in Participants With Selected Advanced Solid TumorsMI, UTView Drugs View Results
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
LY4170156ADC: anti-FRalpha + topoisomerase I inhibitor (exatecan)Clinical Trials
NCT05527184IRecurrent high grade serous ovarian cancer (inc expansion)A Phase 1, First-in-Human, Open-Label, Dose-Escalation and Expansion Study of IMGN151 (Anti-FRα Antibody-drug Conjugate) in Adult Patients With Recurrent Endometrial Cancer and Recurrent, High-Grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancersCA, CO, FL, OK, TN, TXView Drugs
Drug(s) in Trial Other Drug Names Main Known Action Drug Status
IMGN151ADC: anti-FRalpha + microtubule destabilizer (DM21)Clinical Trials

If you have any questions or would like help with your search, please call us at: 858-264-6889 or email us at patientsupport@clearityfoundation.org.